Analyzing the potential therapeutic mechanism of Huashi Baidu Decoction on severe COVID-19 through integrating network pharmacological methods

Zhu, Yiwei Tony; Yan, Xiaofeng; Ye, Tingjie; Hu, Jing; Wang, Xiaoling; Qiu, Fengjun; Liu, Chenghai; Hu, Xudong

doi:10.1016/j.jtcme.2021.01.004

Cited by 30 publications

(9 citation statements)

References 34 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is more suitable to study its mechanism of action by using systematic and holistic research ideas and extracting the complex system from the system for the development of anti-epidemic drugs. Based on the summary of previous studies and the excavation of essential oil components of A. tsao-ko , it can be used as a low-cost drug for the development of COVID-19 prevention ( Zhu et al, 2021 , Lee et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Amomum tsao-ko essential oil, a novel anti-COVID-19 Omicron spike protein natural products: A computational study

Liu

et al. 2022

Arabian Journal of Chemistry

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Amomum tsao-ko essential oil, a novel anti-COVID-19 Omicron spike protein natural products: A computational study

Liu

et al. 2022

Arabian Journal of Chemistry

View full text Add to dashboard Cite

“…In recent years, A. tsaoko has been considered to have a broader utilization value and proven to have biological activities, such as anti-oxidation [2,3], antibacterial [4], anti-inflammation [5], antidiabetic [6], anti-tumor [7], and anticonvulsant properties [8]. In addition, A. tsaoko is a TCM that has been prescribed for the treatment of COVID-19 [9][10][11][12]. As an aromatic Chinese herbal medicine used for both medicinal and edible purposes, essential oil is the most important active ingredient of A. tsaoko, and its content determines the quality of A. tsaoko (Pharmacopoeia of the People's Republic of China, 2020).…”

mentioning

confidence: 99%

De novo transcriptome assembly, gene annotation, and EST-SSR marker development of an important medicinal and edible crop, Amomum tsaoko (Zingiberaceae)

Meng

Lei

et al. 2022

BMC Plant Biol

View full text Add to dashboard Cite

Background Amomum tsaoko is a medicinal and food dual-use crop that belongs to the Zingiberaceae family. However, the lack of transcriptomic and genomic information has limited the understanding of the genetic basis of this species. Here, we performed transcriptome sequencing of samples from different A. tsaoko tissues, and identified and characterized the expressed sequence tag-simple sequence repeat (EST-SSR) markers. Results A total of 58,278,226 high-quality clean reads were obtained and de novo assembled to generate 146,911 unigenes with an N50 length of 2002 bp. A total of 128,174 unigenes were successfully annotated by searching seven protein databases, and 496 unigenes were identified as annotated as putative terpenoid biosynthesis-related genes. Furthermore, a total of 55,590 EST-SSR loci were detected, and 42,333 primer pairs were successfully designed. We randomly selected 80 primer pairs to validate their polymorphism in A. tsaoko; 18 of these primer pairs produced distinct, clear, and reproducible polymorphisms. A total of 98 bands and 96 polymorphic bands were amplified by 18 pairs of EST-SSR primers for the 72 A. tsaoko accessions. The Shannon's information index (I) ranged from 0.477 (AM208) to 1.701 (AM242) with an average of 1.183, and the polymorphism information content (PIC) ranged from 0.223 (AM208) to 0.779 (AM247) with an average of 0.580, indicating that these markers had a high level of polymorphism. Analysis of molecular variance (AMOVA) indicated relatively low genetic differentiation among the six A. tsaoko populations. Cross-species amplification showed that 14 of the 18 EST-SSR primer pairs have transferability between 11 Zingiberaceae species. Conclusions Our study is the first to provide transcriptome data of this important medicinal and edible crop, and these newly developed EST-SSR markers are a very efficient tool for germplasm evaluation, genetic diversity, and molecular marker-assisted selection in A. tsaoko.

show abstract

“…Several network pharmacology analysis studies had preliminarily explained the possible therapeutic mechanism of Huanshibaidu granule. A study found that Huashibaidu granule might treat severe COVID-19 through 45 potential target genes including 13 hub target genes ( 12 ). Other studies had found that quercetin and ursolic acid contained in Huashibaidu granule could inhibit COVID-19 by down-regulating IL-6 ( 13 ), quercetin and gallic acid could inhibit COVID-19 by down-regulating angiotensin converting enzyme II (ACE2) ( 14 ), and baicalein and quercetin were the top two compounds that had effect to treat COVID-19 mainly through TNF, PI3K–Akt and MAPK signaling pathway ( 15 ).…”

Section: Discussionmentioning

confidence: 99%

Chinese Medicine Formula Huashibaidu Granule Early Treatment for Mild COVID-19 Patients: An Unblinded, Cluster-Randomized Clinical Trial

Chen

Yang

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Background: Previous research suggested that Chinese Medicine (CM) Formula Huashibaidu granule might shorten the disease course in coronavirus disease 2019 (COVID-19) patients. This research aimed to investigate the early treatment effect of Huashibaidu granule in well-managed patients with mild COVID-19.Methods: An unblinded cluster-randomized clinical trial was conducted at the Dongxihu FangCang hospital. Two cabins were randomly allocated to a CM or control group, with 204 mild COVID-19 participants in each cabin. All participants received conventional treatment over a 7 day period, while the ones in CM group were additionally given Huashibaidu granule 10 g twice daily. Participants were followed up to their clinical endpoint. The primary outcome was worsening symptoms before the clinical endpoint. The secondary outcomes were cure and discharge before the clinical endpoint and alleviation of composite symptoms after the 7 days of treatment.Results: All 408 participants were followed up to their clinical endpoint and included in statistical analysis. Baseline characteristics were comparable between the two groups (P > 0.05). The number of worsening patients in the CM group was 5 (2.5%), and that in the control group was 16 (7.8%) with a significant difference between groups (P = 0.014). Eight foreseeable mild adverse events occurred without statistical difference between groups (P = 0.151).Conclusion: Seven days of early treatment with Huashibaidu granule reduced the likelihood of worsening symptoms in patients with mild COVID-19. Our study supports Huashibaidu granule as an active option for early treatment of mild COVID-19 in similar well-managed medical environments.Clinical Trial Registration:www.chictr.org.cn/showproj.aspx?proj=49408, identifier: ChiCTR2000029763.

show abstract

Analyzing the potential therapeutic mechanism of Huashi Baidu Decoction on severe COVID-19 through integrating network pharmacological methods

Cited by 30 publications

References 34 publications

Amomum tsao-ko essential oil, a novel anti-COVID-19 Omicron spike protein natural products: A computational study

Amomum tsao-ko essential oil, a novel anti-COVID-19 Omicron spike protein natural products: A computational study

De novo transcriptome assembly, gene annotation, and EST-SSR marker development of an important medicinal and edible crop, Amomum tsaoko (Zingiberaceae)

Chinese Medicine Formula Huashibaidu Granule Early Treatment for Mild COVID-19 Patients: An Unblinded, Cluster-Randomized Clinical Trial

Contact Info

Product

Resources

About